
Celltrion Highlights Two-Year Analysis Supporting Dose Escalation for CT-P13 SC in IBD
Celltrion has announced two-year findings from a post-hoc analysis of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC), presented at United European Gastroenterology (UEG) Week 2024 in Vienna. The analysis shows that dose escalation of subcutaneous infliximab (CT-P13 SC) is effective for…













